**29th Scientific Symposium of the Austrian Pharmacological Society (APHAR)**

**Krems an der Donau, Austria, 22 – 24 September 2025**

## ABSTRACT FORM

**Part A (Administrative details)**

|  |  |
| --- | --- |
| **Presenting Author:** |  |
| Ms / Mr *(please tick)* | 🞏 Ms/Mrs 🞏 Mr 🞏 other: \_\_\_\_\_\_\_\_\_\_\_ |
| Surname: |  |
| Given name(s) |  |
| E-mail: |  |
| Age of presenting author: | 🞏 ≤ 35 years 🞏 > 35 years |
|  |  |
| **Corresponding Author** (Principal investigator): | |
| Full name: |  |
| E-mail: *(This e-mail will be published with the abstract)* |  |
|  |  |
| **Preferences** etc. | |
| At least one of the (co)authors must be a member of one of the organising societies.  *Please check one* [x] | 🞏 APHAR 🞏 APHAR Section of Clinical Pharmacology  ***Initials of authors*** *who are members of APHAR:* \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  |  |
| **Preferred** type of presentation: | 🞏 No preference 🞏 Short oral communication 🞏 Poster |
|  | **🡱** *The* ***final decision*** *on presentation type will be made on the basis of program requirements* |
| Do you wish the abstract to be published? | 🞏 Yes (**default**) 🞏 No |
|  | *Abstracts will be published online in* Intrinsic Activity *(*[*www.IntrinsicActivity.org*](http://www.IntrinsicActivity.org)*)* |
| *Please check* [x] | 🞏 I confirm that this abstract has not been published before. (required) |
|  |  |
| *Please check* [x] | 🞏 I give permission that the data supplied above may be used by APHAR for the purpose of communication with me and the corresponding author with respect to abstract processing / publication and information about the Scientific Symposium of APHAR. (required) |

**🡪 *continue on next page* 🡪**

**Part B (Abstract details)**

***Please follow Instructions for Authors* 🡪**<http://www.IntrinsicActivity.org/instructions/IA-Instructions-MA.pdf>

|  |  |
| --- | --- |
| **Title of abstract** *Use sentence case,* ***no****full stop at the end* |  |
|  |  |
| **Authors *Full first and last names*** *of all authors; presenting author should be first author; make sure to use correct spelling.* |  |
|  | **🡱** *Use diacritical marks on characters (á à â ä ć č ç é è ê ğ í ì î ı ó ò ö ő ś ş š ú ù ü ű ž etc.) as appropriate* |
| **Affiliations** *Where there are multiple affiliations, the institutes should appear in the order of author names and should be identified by appropriate superscript numbers.* |  |
|  |  |
| **Main text**  *Normal length of text is* ***300–500 words.*** *(max.length: one A4 page in final formatting of APHAR publishing organ: Intrinsic Activity).*  *Please follow the* ***Instructions for Authors*** *(link below).*  **Abstracts will be edited** for publication in *Intrinsic Activity*.  Note: The abstract field on the right is resizeable so that longer texts will  fit into this form. | **Background:** *[One paragraph of text mandatory]*  **Methods:** *[One paragraph of text mandatory]*  **Results:** *[One paragraph of text mandatory]*  **Discussion:** *[One paragraph of text mandatory]*  **Acknowledgements:** *[(grant support) One sentence if needed, otherwise mark as ‘DELETED’]*  **Keywords:** *[Please provide at leat 3 (or more) keywords for indexing]*  **References:** *[Include references ONLY if they are essential, otherwise delete]* |

**🡺 *Instructions for Authors:*** <http://www.IntrinsicActivity.org/instructions/IA-Instructions-MA.pdf>

*Deadline for submission: extended to* ***30 June 2025***

***ELECTRONIC SUBMISSION via***🡺 ***e-mail:*** [***lehre-pharmakologie@medunigraz.at***](mailto:lehre-pharmakologie@medunigraz.at)🡸  
(please *do NOT convert* the form to any other format)

For additional information see next page 🡦

**Part C (Further information)**

* **Abstracts will be edited** for publication in *Intrinsic Activity*, the publication medium of the Austrian Pharmacological Society.
* **After submission**, presenting and corresponding authors will receive a copy of the edited abstract which should be checked carefully for errors.
* **Editorial queries** must be answered appropriately.
* **Corrections** should be submitted within one week to [lehre-pharmakologie@medunigraz.at](mailto:lehre-pharmakologie@medunigraz.at);   
  if further corrections or amendments may be submitted until the fixed date of publication. However, no changes to the abstracts will be possible once they are published in final form.
* If you have indicated that you do not wish that your abstract be published, you can change your mind until the time of publication of the proceedings (ca. one week before date of meeting).

**🡺 *Instructions for Authors:*** <http://www.IntrinsicActivity.org/instructions/IA-Instructions-MA.pdf>

*Deadline for submission: extended to* ***30 June 2025***

***ELECTRONIC SUBMISSION via***🡺 ***e-mail:*** [***lehre-pharmakologie@medunigraz.at***](mailto:lehre-pharmakologie@medunigraz.at)🡸

(please ***do NOT*** *convert* the form to any other format)